Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Study Proposal:
Other drugs where synergy with Gemcitabine has been observed are Cisplatinum, Taxol,
Taxotere, Etoposide and alkylating agents. However in view of Oxaliplatin's superior activity
as a single agent against lymphoma, the combination of Gemcitabine with Oxaliplatin is more
attractive and should be explored in this group of disorders. Based on these data and
considering the advantage of its favorable toxicity profile, we propose a phase II study in
patients with either refractory or relapsing aggressive non-Hodgkin's lymphomas including
peripheral T-cell lymphomas which are known to have a poor outcome when compared with
equivalent aggressive B-cell lymphomas.